STERIS plc (STE) Market Cap & Valuation Ratios
STERIS plc (STE) has a market cap of $22.6B, a trailing P/E of 28.4 and a price-to-sales ratio of 3.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STESTERIS plcFollow STE — free
—
Price chart with a free account
- Market cap
- 22.6B
- P/E TTM
- 28.4
- Dividend yield
- 1.1%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| STE | 23 | 28.4 | 4.0 | 14.7 | 4.1% | +8% | 19% | 10% |
| EW | 51 | 51.2 | 7.3 | 29.5 | 2.8% | +15% | 22% | 12% |
| GEHC | 32 | 16.4 | 1.9 | 12.1 | 4.9% | +7% | 13% | 12% |
| DXCM | 29 | 30.9 | 5.9 | 21.1 | 4.8% | +16% | 23% | 33% |
| ZBH | 19 | 23.9 | 3.0 | 11.2 | 6.4% | +9% | 14% | 5% |
| PEN | 13 | 79.7 | 8.1 | 59.3 | 1.7% | +18% | 12% | 13% |
| GMED | 11 | 20.9 | 3.3 | 11.2 | 6.9% | +20% | 20% | 12% |
| GKOS | 11 | — | 17.0 | — | -0.1% | +42% | -32% | -31% |
| PODD | 10 | 27.9 | 3.5 | 17.5 | 2.7% | +29% | 17% | 22% |
| BIO | 9.9 | — | 3.7 | 42.7 | 3.6% | +1% | 2% | 0.4% |
| BRKR | 8.8 | — | 3.0 | 52.2 | 1.1% | +2% | -0.9% | -0.7% |
| Median of these 10 | 27.9 | 3.6 | 21.1 | 3.2% | +15% | 14% | 12% |
P/E 28.4 vs. a peer median of 27.9; EV/Sales 4.0 vs. 3.6. STE's own P/E sits at the 7th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesGKOS and BIO and BRKR have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
STERIS plc — questions
- What is STERIS plc's market cap?
- $22.6B.
- What is STERIS plc's P/E ratio?
- 28.4 on trailing twelve-month earnings to 2026-06-30.
- What is STERIS plc's price-to-sales ratio?
- 3.8.
Every figure on this page comes from STERIS plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.